Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Lung Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 84Etoposide 31Daunorubicin 31Mitoxantrone 26Idarubicin 26Filgrastim 24Busulfan 20Peripheral Blood Stem Cell Transplantation 19Cyclophosphamide 17fludarabine phosphate 15Gemtuzumab 14tipifarnib 11Azacitidine 11Methotrexate 10Clofarabine 10sargramostim 9Gene Expression Profiling 9Flow Cytometry 9Cyclosporine 9Tacrolimus 8Radiotherapy 8Granulocyte Colony-Stimulating Factor 7Decitabine 7Antilymphocyte Serum 7alvocidib 6Topotecan 6Bortezomib 6Arsenic Trioxide 6valspodar 5aldesleukin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Monocytic, Acute × Drug Screening Assays, Antitumor × Clear all
NCT01872819 2018-07-11

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

University of Washington

Phase NA Completed
16 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡